OOIR: Observatory of International Research

Papers

(The median citation count of Translational Neurodegeneration is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-03-01 to 2025-03-01.)

Article	Citations
Retraction Note: Alpha-synuclein overexpression in the olfactory bulb initiates prodromal symptoms and pathology of Parkinson’s disease	232
Clinical evidence of human pathogens implicated in Alzheimer’s disease pathology and the therapeutic efficacy of antimicrobials: an overview	218
Dual role of brain-derived extracellular vesicles in dementia-related neurodegenerative disorders: cargo of disease spreading signals and diagnostic-therapeutic molecules	152
Metabolic changes in an animal model of amyotrophic lateral sclerosis evaluated by [18F]-FDG positron emission tomography	131
Seed amplification assay of nasal swab extracts for accurate and non-invasive molecular diagnosis of neurodegenerative diseases	103
An AARS1 variant identified to cause adult-onset leukoencephalopathy with neuroaxonal spheroids and pigmented glia	84
Alpha-synuclein seeding shows a wide heterogeneity in multiple system atrophy	77
TRPV1 alleviates APOE4-dependent microglial antigen presentation and T cell infiltration in Alzheimer's disease	70
N6-methyladenosine-modified circRIMS2 mediates synaptic and memory impairments by activating GluN2B ubiquitination in Alzheimer's disease	69
Inhibiting tau-induced elevated nSMase2 activity and ceramides is therapeutic in an Alzheimer’s disease mouse model	67
Dietary fasting and time-restricted eating in Huntington’s disease: therapeutic potential and underlying mechanisms	63
Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer’s disease	60
Predictability of polygenic risk score for progression to dementia and its interaction with APOE ε4 in mild cognitive impairment	56
The use of fibroblasts as a valuable strategy for studying mitochondrial impairment in neurological disorders	54
Targeting galectin-3 to counteract spike-phase uncoupling of fast-spiking interneurons to gamma oscillations in Alzheimer’s disease	53
Circadian disruption and sleep disorders in neurodegeneration	52
Ultrasensitive assays for detection of plasma tau and phosphorylated tau 181 in Alzheimer’s disease: a systematic review and meta-analysis	52
Inhibition of lysine methyltransferase G9a/GLP reinstates long-term synaptic plasticity and synaptic tagging/capture by facilitating protein synthesis in the hippocampal CA1 area of APP/PS1 mouse mode	52
Analysis of human brain tissue derived from DBS surgery	50
Updates in Alzheimer's disease: from basic research to diagnosis and therapies	45
p85S6K sustains synaptic GluA1 to ameliorate cognitive deficits in Alzheimer’s disease	44
Redox dysregulation as a driver for DNA damage and its relationship to neurodegenerative diseases	43
SGLT2 inhibitors: a novel therapy for cognitive impairment via multifaceted effects on the nervous system	42
Cellular senescence in Alzheimer’s disease: from physiology to pathology	42
Neuronal and synaptic adaptations underlying the benefits of deep brain stimulation for Parkinson's disease	41

LRRK2 mutant knock-in mouse models: therapeutic relevance in Parkinson's disease	41
Argyrophilic grain disease is common in older adults and may be a risk factor for suicide: a study of Japanese forensic autopsy cases	41
Early life adversity as a risk factor for cognitive impairment and Alzheimer’s disease	39
Life and disease status of patients with Parkinson’s disease during and after zero-COVID in China: an online survey	38
Gut microbiome, cognitive function and brain structure: a multi-omics integration analysis	38
Correction: Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia	38
Genetic spectrum and clinical features in a cohort of Chinese patients with autosomal recessive cerebellar ataxias	37
Can exercise benefits be harnessed with drugs? A new way to combat neurodegenerative diseases by boosting neurogenesis	36
SARS-CoV-2 membrane protein induces neurodegeneration via affecting Golgi-mitochondria interaction	36
Perivascular spaces relate to the course and cognition of Huntington’s disease	36
Overlaps and divergences between tauopathies and synucleinopathies: a duet of neurodegeneration	35
Elevated plasma and CSF neurofilament light chain concentrations are stabilized in response to mutant huntingtin lowering in the brains of Huntington’s disease mice	33
A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer’s disease	33
Ultrasensitive detection of TDP-43 and amyloid-β protein aggregates using micelle-assisted seed amplification assay	33
Astrocytes contribute to toll-like receptor 2-mediated neurodegeneration and alpha-synuclein pathology in a human midbrain Parkinson’s model	32
Endosomal traffic disorders: a driving force behind neurodegenerative diseases	32
Brain metabolism in Alzheimer’s disease: biological mechanisms of exercise	31
Pharmacological inhibition of asparaginyl endopeptidase by δ-secretase inhibitor 11 mitigates Alzheimer’s disease-related pathologies in a senescence-accelerated mouse model	31
Associations of AT(N) biomarkers with neuropsychiatric symptoms in preclinical Alzheimer’s disease and cognitively unimpaired individuals	31
CRISPR/dCas9-Dnmt3a-mediated targeted DNA methylation of APP rescues brain pathology in a mouse model of Alzheimer’s disease	30
Effects of transcranial ultrasound stimulation pulsed at 40 Hz on Aβ plaques and brain rhythms in 5×FAD mice	29
Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia	29
Cerebrospinal fluid cyclase-associated protein 2 is increased in Alzheimer’s disease and correlates with tau pathology	28
Why do ‘OFF’ periods still occur during continuous drug delivery in Parkinson’s disease?	28
Links between COVID-19 and Parkinson’s disease/Alzheimer’s disease: reciprocal impacts, medical care strategies and underlying mechanisms	28
Application of antisense oligonucleotide drugs in amyotrophic lateral sclerosis and Huntington’s disease	28
Roles of physical exercise in neurodegeneration: reversal of epigenetic clock	27
COVID-19 and Alzheimer’s disease: how one crisis worsens the other	26
Impaired glymphatic function in the early stages of disease in a TDP-43 mouse model of amyotrophic lateral sclerosis	26
Neurofilament light chain is increased in the parahippocampal cortex and associates with pathological hallmarks in Parkinson’s disease dementia	26
Disruption of orbitofrontal-hypothalamic projections in a murine ALS model and in human patients	26
Dense core vesicle markers in CSF and cortical tissues of patients with Alzheimer’s disease	26
Ultrasensitive detection of aggregated α-synuclein using quiescent seed amplification assay for the diagnosis of Parkinson’s disease	26
Patient-derived iPSC models of Friedreich ataxia: a new frontier for understanding disease mechanisms and therapeutic application	24
Impaired dynamic interaction of axonal endoplasmic reticulum and ribosomes contributes to defective stimulus–response in spinal muscular atrophy	24
Death-associated protein kinase 1 as a therapeutic target for Alzheimer's disease	24
An open-label multiyear study of sargramostim-treated Parkinson’s disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbers	23
Oligodendrocyte progenitor cells in Alzheimer’s disease: from physiology to pathology	23
Agomirs upregulating carboxypeptidase E expression rescue hippocampal neurogenesis and memory deficits in Alzheimer’s disease	23
Recombinant SMN protein synergizes with spinal muscular atrophy therapy to counteract pathological motor neuron phenotypes	22
Impact of seed amplification assay and surface-enhanced Raman spectroscopy combined approach on the clinical diagnosis of Alzheimer’s disease	22
Early GCase activity is a predictor of long-term cognitive decline in Parkinson’s disease	22
α-Synuclein seeding amplification assays for diagnosing synucleinopathies: an innovative tool in clinical implementation	22
GCN2 inhibition reduces mutant SOD1 clustering and toxicity and delays disease progression in an amyotrophic lateral sclerosis mouse model	21
Role of dopamine in the pathophysiology of Parkinson’s disease	21
Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial	21
Correction: Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations	20
NLRP3 inflammasome in cognitive impairment and pharmacological properties of its inhibitors	20
TDP-43 dysregulation and neuromuscular junction disruption in amyotrophic lateral sclerosis	20
Clinical and genetic characterization of a large cohort of patients with Wilson’s disease in China	20

Language training for oral and written naming impairment in primary progressive aphasia: a review	19
α-Synuclein conformers reveal link to clinical heterogeneity of α-synucleinopathies	19
A novel transgenic mouse line with hippocampus-dominant and inducible expression of truncated human tau	19
Correction: Targeting the overexpressed mitochondrial protein VDAC1 in a mouse model of Alzheimer’s disease protects against mitochondrial dysfunction and mitigates brain pathology	19
Cellular senescence as a key contributor to secondary neurodegeneration in traumatic brain injury and stroke	18
The microglial P2Y6 receptor as a therapeutic target for neurodegenerative diseases	18
Parkinson's disease and glucose metabolism impairment	17
Retraction Note: Asiaticoside, a trisaccaride triterpene induces biochemical and molecular variations in brain of mice with parkinsonism	17
The C. elegans gba-3 gene encodes a glucocerebrosidase that exacerbates α-synuclein-mediated impairments in deletion mutants	17
In vivo diagnosis of TDP-43 proteinopathies: in search of biomarkers of clinical use	16
Janus kinase inhibitors are potential therapeutics for amyotrophic lateral sclerosis	16
Reciprocal effects of alpha-synuclein aggregation and lysosomal homeostasis in synucleinopathy models	16
Blood–brain barrier alterations and their impact on Parkinson’s disease pathogenesis and therapy	15
Aquaporin-4 as a cerebrospinal fluid biomarker of Alzheimer’s disease	15
Extracellular vesicles, from the pathogenesis to the therapy of neurodegenerative diseases	15
Loss of tau expression attenuates neurodegeneration associated with α-synucleinopathy	15
Parkinson’s disease and gut microbiota: from clinical to mechanistic and therapeutic studies	14
Disruption of the white matter structural network and its correlation with baseline progression rate in patients with sporadic amyotrophic lateral sclerosis	14
Alleviating the unwanted effects of oxidative stress on Aβ clearance: a review of related concepts and strategies for the development of computational modelling	14
Modulating arousal to overcome gait impairments in Parkinson’s disease: how the noradrenergic system may act as a double-edged sword	14
Genetic heterogeneity on sleep disorders in Parkinson’s disease: a systematic review and meta-analysis	14
Several miRNAs derived from serum extracellular vesicles are potential biomarkers for early diagnosis and progression of Parkinson’s disease	14
Associations of cerebrospinal fluid amyloidogenic nanoplaques with cytokines in Alzheimer’s disease	14
Correction to: Neurodegenerative diseases: a hotbed for splicing defects and the potential therapies	13
Optimization of cerebral organoids: a more qualified model for Alzheimer’s disease research	13
Research progress on the role of extracellular vesicles in neurodegenerative diseases	13
Update on the pathological roles of prostaglandin E2 in neurodegeneration in amyotrophic lateral sclerosis	13
The role of pathological tau in synaptic dysfunction in Alzheimer’s diseases	12
Defective mitophagy and the etiopathogenesis of Alzheimer’s disease	12
N-terminus α-synuclein detection reveals new and more diverse aggregate morphologies in multiple system atrophy and Parkinson’s disease	12
Emerging role of senescent microglia in brain aging-related neurodegenerative diseases	12
CD2AP deficiency aggravates Alzheimer’s disease phenotypes and pathology through p38 MAPK activation	12
APOE ε4-dependent effects on the early amyloid pathology in induced neurons of patients with Alzheimer’s disease	12
Critical role of ROCK1 in AD pathogenesis via controlling lysosomal biogenesis and acidification	12
Effectiveness and mechanisms of adipose-derived stem cell therapy in animal models of Parkinson’s disease: a systematic review and meta-analysis	11
Refining α-synuclein seed amplification assays to distinguish Parkinson’s disease from multiple system atrophy	11
A novel plasma p-tau181 assay as a specific biomarker of tau pathology in Alzheimer's disease	11
Correction: Starburst amacrine cells, involved in visual motion perception, lose their synaptic input from dopaminergic amacrine cells and degenerate in Parkinson’s disease patients	11
AMPA receptor diffusional trapping machinery as an early therapeutic target in neurodegenerative and neuropsychiatric disorders	11
CRISPR base editing-mediated correction of a tau mutation rescues cognitive decline in a mouse model of tauopathy	11
Correction: A novel transgenic mouse line with hippocampus-dominant and inducible expression of truncated human tau	11
Metabolic regulation of microglial phagocytosis: Implications for Alzheimer's disease therapeutics	11
Neurodegenerative diseases: a hotbed for splicing defects and the potential therapies	10
Remodeling of astrocyte secretome in amyotrophic lateral sclerosis: uncovering novel targets to combat astrocyte-mediated toxicity	10
LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression	10
Starburst amacrine cells, involved in visual motion perception, lose their synaptic input from dopaminergic amacrine cells and degenerate in Parkinson’s disease patients	10
The interaction between ageing and Alzheimer's disease: insights from the hallmarks of ageing	10
Second-generation anti-amyloid monoclonal antibodies for Alzheimer’s disease: current landscape and future perspectives	10
Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations	10
Differential seeding and propagating efficiency of α-synuclein strains generated in different conditions	10